DC
DAWN

Diametric Capital’s Day One Biopharmaceuticals DAWN Stock Holding History

Diametric Capital’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-38,465
Closed -$271K – 412
2025
Q3 		$271K Sell
38,465
-11,476
-23% -$79K 0.1% 256
2025
Q2 		$325K Buy
49,941
+25,465
+104% +$175K 0.17% 168
2025
Q1 		$194K Buy
24,476
+13,748
+128% +$148K 0.23% 138
2024
Q4 		$136K Sell
10,728
-6,995
-39% -$97.3K 0.09% 262
2024
Q3 		$247K Buy
17,723
+2,700
+18% +$38.5K 0.12% 248
2024
Q2 		$207K Sell
15,023
-3,773
-20% -$55.2K 0.11% 272
2024
Q1 		$311K Buy
+18,796
New +$281K 0.17% 148

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Diametric Capital's DAWN Position: Q4 2025 in Review

Diametric Capital sold out of Day One Biopharmaceuticals (DAWN) in Q4 2025, closing a stake of 38,465 shares — an estimated $271K sold.

Diametric Capital first reported a position in DAWN in Q1 2024 and held it in 7 quarters. The position peaked at $325K in Q2 2025. 183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

  • Diametric Capital reported no remaining Day One Biopharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Diametric Capital sold 38,465 Day One Biopharmaceuticals shares in Q4 2025, an estimated $271K.
  • Diametric Capital first reported a position in Day One Biopharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Diametric Capital's Day One Biopharmaceuticals position peaked at $325K in Q2 2025.
  • 183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on Diametric Capital's 13F filing for Q4 2025, filed 13 Feb 2026.